Germany · Delayed Price · Currency is EUR thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
Secured a major 300 MW green hydrogen order, raising order intake guidance and confirming strong commercial momentum. Updated guidance reflects higher project costs and a US contract termination, impacting EBIT, but the business remains stable with a robust chlor-alkali segment.
-
The AGM highlighted strong financial results, strategic focus on green hydrogen and Chlor-Alkali, and robust governance. All agenda items passed with large majorities, while management addressed regulatory, market, and project risks, emphasizing innovation and international expansion.
-
Q1 results were in line with expectations, with sales and order intake down year-on-year but profitability supported by cost control and improved project mix. The project pipeline is more focused, with major opportunities in Europe and India, and full-year guidance is confirmed.
Fiscal Year 2025
-
Sales reached EUR 845 million with positive EBIT of EUR 2 million, driven by record chlor-alkali performance and improved green hydrogen margins. Outlook for 2025-2026 anticipates lower sales but robust order intake, with continued focus on cost control and innovation.
-
Sales and EBIT guidance were raised following a strong nine-month performance, with robust project execution in both core alkali and green hydrogen segments. Order intake remains subdued in green hydrogen due to project delays, but a solid backlog and new technology acquisitions support future growth.
-
Strong sales and EBIT growth were achieved in both chlor-alkali and green hydrogen segments, with Europe leading project opportunities amid regulatory support. Financials remain robust, and guidance for the year is confirmed, though U.S. policy uncertainty poses risks.
-
Record Q1 sales and improved profitability were driven by strong execution in both green hydrogen and chlor-alkali segments. Guidance for the year is confirmed, with Europe highlighted as the key growth region for green hydrogen, and management transitions underway.
Fiscal Year 2024
-
Record sales and strong order intake were driven by major green hydrogen and chlor-alkali projects, with robust financials and a solid cash position. Guidance for FY 2024-25 anticipates continued growth, though regulatory and market uncertainties remain.
-
Record Q3 sales and strong order intake were driven by major project milestones in both AWE and chlor-alkali, but regulatory delays and market uncertainties led to the withdrawal of next year's AWE guidance. Full-year sales and EBIT guidance for 2023-2024 are confirmed.